Gilead’s UC Pill Hits Trial Goal, Stock Still SlipsBy Martin Holloway19/10/2026 Gilead’s ulcerative colitis trial met its main goal, but GILD shares fell 1.42% as RBC said the readout was unlikely to move the stock.
